Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
-
Paroxysmal or sustained atrial fibrillations profoundly acti
2022-07-12
Paroxysmal or sustained atrial fibrillations profoundly activate platelets and induce coagulation factors in the heart (Choudhury and Lip, 2003). Accumulating factor Xa and downstream thrombin in the fibrillating left atrium activate PAR1 and/or PAR2 signaling to modulate electrical characteristics
-
A few previous studies have examined
2022-07-12
A few previous studies have examined Factor Xa inhibitors for VTE prophylaxis in hip fracture patients. In a 2001 paper, Eriksson et al. studied 1250 patients with hip fractures that had been randomized to either postoperative Factor Xa inhibitor or enoxaparin [13]. Each patient received bilateral v
-
Two recently developed highly specific EZH enzymatic inhibit
2022-07-12
Two recently developed, highly specific EZH2 enzymatic inhibitors, GSK126 and EPZ-6438, are currently in clinical trials for treating lymphomas (Kim and Roberts, 2016). Although these EZH2 inhibitors have shown antitumor effects in lymphoma cells with enzyme-activating mutations of EZH2 (Knutson et
-
glycoprotein inhibitors br Mammalian chromosomal DNA binds t
2022-07-12
Mammalian chromosomal DNA binds to various proteins and the DNA-protein complexes form DNA packaging units, called nucleosomes. Histones are the chief protein components of nucleosomes and perform pivotal functions in chromosomal gene regulation. Moreover, many types of chemical modifications of h
-
cholinesterase inhibitor MK cyclobutylpiperidin yl oxyphenyl
2022-07-12
MK-3134 (3-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-methyl-5-(trifluoromethyl)quinazolin-4-one) was synthesized by Merck, as the structurally constrained analogue of MK-0249 (Nagase et al., 2008). This H3R inverse agonist has MW 457.49, seven HBA, and MLogP 4.58, with one violation in terms of dr
-
br Authors contribution br Funding sources This
2022-07-12
Authors' contribution Funding sources This study was supported by CDC intramural funding. Publication costs are funded by an internal program of CDC. MAT was supported by funds from the Association of Public Health Laboratories and CDC (APHL–CDC) Bioinformatics Fellowship Program. Competing
-
Here we report the genomic structure and
2022-07-12
Here we report the genomic structure and the phylogenetic analysis of testis-specific Ser/Thr kinase haspin gene. Materials and methods Results Discussion The isolation and analysis of haspin genomic DNA showed that haspin was an intron-less gene and localized in an intron of integrin αM29
-
As previously discussed even though glucose is the
2022-07-12
As previously discussed, even though glucose is the major fuel of the brain, neuronal cells may use alternative fuels such as ketone bodies in metabolically challenging situations in which glucose availability is limited [6]. Ketogenesis takes place mainly in the liver, although astrocytes can also
-
AM251 An alternative approach to improving pharmacokinetic
2022-07-11
An alternative approach to improving pharmacokinetic profile while retaining high GlyT1 potency was also pursued. Libraries were prepared in which potency enhancing piperidine C4 substituents were combined with clearance lowering truncated alkyl sulfonamides. The result was the discovery of (). Unl
-
In this study we provide biochemical
2022-07-11
In this study we provide biochemical and immunohistochemical evidence for the localization of the glycine transporter GLYT1 in synaptic vesicles. Previously, it was thought that GLYT1 was exclusively a glial protein (Zafra et al., 1995a). However, due to a partial discrepancy between mRNA and protei
-
Introduction l Glutamate is a major excitatory neurotransmit
2022-07-11
Introduction l-Glutamate is a major excitatory neurotransmitter in the mammalian central nervous system (CNS) that contributes not only to fast synaptic neurotransmission, but also to complex physiological processes like memory, learning, plasticity, and neuronal cell death [30], [81]. Glutamate is
-
Introduction As per WHO report in more than
2022-07-11
Introduction As per WHO report, in 2014 more than 422 million peoples were living with diabetes and according to International Diabetes Federation, by 2045 this figure would reach 693 million [1,2]. Diabetes, a fast growing major health problem, is common chronic, metabolic disease characterized by
-
The effect of GCK NES mutations on enzyme kinetics and
2022-07-11
The effect of GCK-NES mutations on enzyme kinetics and protein stability might account for the hyperglycaemia that characterizes MODY2 patients, since reduced GCK activity would increase the threshold for glucose stimulated insulin release in beta-cells [31,37,49]. However, a more in depth functiona
-
br Conclusion In the present study we found that the
2022-07-11
Conclusion In the present study, we found that the majority of commercially available antibodies and antibody-based tools against galanin and its receptors that we tested do not meet validation requirements. Therefore, critical validation of these tools by the user is essential before being used
-
After the successful development of molecular targeted
2022-07-11
After the successful development of molecular targeted drugs in lung adenocarcinoma, substantial efforts have been made to provide similar targeted drugs in lung squamous-cell carcinoma. Because FGFR gene alteration is the most frequent occurrence in squamous-cell carcinoma, targeted therapies for F
14780 records 342/986 page Previous Next First page 上5页 341342343344345 下5页 Last page